Antraliv - instructions for use, doses, side effects, contraindications

One capsule contains: phospholipids (Lipoid PPL-400) (containing phosphatidylcholine at least 73%, phosphatidylethanolamine 7%, etc.) - 300 mg in terms of 100% of the content of polyenaspsenic phospholipids from soya lecithin (fraction PPL), soybean oil (soybean oil) - up to 500 mg.

Hard gelatin capsules: titanium dioxide (titanium dioxide), iron dye oxide black (ferrous iron oxide), iron dye oxide red (red iron oxide), iron dye oxide yellow (yellow iron oxide), purified water, gelatin.

Description:

Hard gelatin capsules number 0.Body and lid from light brown to brown. The contents of the capsules are a yellow-brown or brown homogeneous mass from the ointment to a more dense consistency with a characteristic odor.

Pharmacotherapeutic group:Hepatoprotective agent

ATX: & nbsp

A.05.C Combination of drugs for the treatment of diseases of the liver and biliary tract

Pharmacodynamics:

Antraliv® has a hepatoprotective effect - protects and repairs damaged liver cells, normalizes lipid and blood glucose levels. Essential phospholipids, which are part of Antraliva®, are ideally combined with natural endogenous phospholipids in chemical structure. They penetrate into the liver cells, penetrating into their membranes.

Antraliv® provides a liver with impaired metabolic activity with the necessary dose of ready-to-assimilate, high-energy essential phospholipids that:

normalize liver function and enzyme activity of liver cells;
reduce the level of energy expenditure of the liver;
promote the regeneration of liver cells;
transform neutral fats and cholesterol into forms that facilitate their metabolism;
stabilize the physico-chemical properties of bile;
have an antioxidant effect due to the ability to block free radicals by rupturing the double bonds of essential fatty acids that make up the phospholipids.

Indications:

Fatty degeneration of the liver of various etiologies (including diabetes mellitus), violations of lipid metabolism of the liver; chronic hepatitis, cirrhosis; toxic liver damage (alcoholic, narcotic, medicinal); radiation syndrome; psoriasis (as part of combination therapy); gestosis.

Contraindications:

Hypersensitivity to the components of the drug.

Dosing and Administration:

Inside for 2 capsules 2-3 times a day during meals, swallowing whole with enough water. The duration of the course of treatment is at least 3 months, if necessary, the term can be extended or repeated treatment. Maintenance dose - 1 capsule 3 times a day.

With psoriasis (as part of complex therapy) - for 2 weeks 2 capsules 3 times a day.

Side effects:

Very rarely, when taking elevated doses of Antraliva®, there may be a feeling of discomfort in the epigastric region, a loosening of the stool, nausea, gastralgia,allergic reactions.

Overdose:

At present, no cases of drug overdose have been reported.

Interaction:

Cases of interaction or incompatibility with other medicinal products are not described.

Effect on the ability to drive transp. cf. and fur:

Form release / dosage:Capsules 300 mg.

Packaging: For 10 or 15 capsules in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered. By 2, 3, 4, 5, 6, 9 or 10 contour mesh packages together with instructions for medical use of the drug are placed in a pack of cardboard.

Storage conditions:

At a temperature not exceeding 20 ° C.

Keep out of the reach of children.

Shelf life:

2 years. Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:Without recipe

Registration number:LSR-005768/10

Date of registration:23.06.2010 / 07.09.2015

Expiration Date:Unlimited

The owner of the registration certificate:Nizhny Novgorod Chemical and Pharmaceutical Plant, OJSCNizhny Novgorod Chemical and Pharmaceutical Plant, OJSC

Manufacturer: & nbsp

NIZHFARM, JSC Russia

Representation: & nbspNizhpharm, JSCNizhpharm, JSCRussia

Information update date: & nbsp16.08.2017

Illustrated instructions

Instructions

Antralive® (Antraliv)